A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 4
- Study design
- RANDOMIZED · CROSSOVER · OTHER · QUADRUPLE
- Evidence population
- Human clinical study registration
- Participants
- 60
- Population
- ALL · 65 Years
- Duration
- 2025-12-09 to 2026-12-31
- Intervention
- Fisetin followed by Placebo; Placebo followed by Fisetin
- Comparator
- Not reported
- Outcomes measured
- Change in Pittsburgh Fatigability Scale (PFS) — Baseline to Week 2; Change in Pittsburgh Fatigability Scale (PFS) — Baseline to Week 4; Change in Pittsburgh Fatigability Scale (PFS) — Baseline to Week 6; Change in Pittsburgh Fatigability Scale (PFS) — Baseline to Week 12; Change in Patient Reported Outcomes Measurement System (PROMIS) — Baseline to Week 2, Baseline to Week 4, Baseline to W…; Change in Pepper Assessment Tool for Disability (PAT-D) — Baseline to Week 2, Baseline to Week 4, Baseline to Week 6; Change in Expanded Short Physical Performance Battery (eSPPB) — Baseline to Week 2, Baseline to Week 4, Baseline to Wee…; Change in 6-minute Walk Distance — Baseline to Week 2, Baseline to Week 4, Baseline to Week 6; Change in Fried Frailty Phenotype Score — Baseline to Week 2, Baseline to Week 4, Baseline to Week 6; Change in Longitudinal Aging Study Amsterdam (LASA) Sedentary Behavior Questionnaire — Baseline to Week 2, Baseline to…; Change in PROMIS Global Health Short Form — Baseline to Week 2, Baseline to Week 4, Baseline to Week 6; Medication Adherence Rate — Week 2, Week 5
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Cancer and ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Title supplies ageing or longevity context.
- Fisetin · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.
Automated source check 100% · update recency 85%. These figures help sort records; they are not medical ratings.